XtalPi Enters into Collaboration with Eli Lilly to Discover Drug Candidates Using Artificial Intelligence and Robotics Platform

By Ashish Tripathi

Pharma Deals Review: Vol 2023 Issue 6 (Table of Contents)

Published: 20 Jun-2023

DOI: 10.3833/pdr.v2023.i6.2792     ISSN: 1756-7874

Section: Research & Development



Eli Lilly has entered into an artificial intelligence (AI) drug discovery collaboration with XtalPi, which is worth up to US$250 M and will provide Lilly with access to XtalPi’s ID4Inno™ drug discovery platform to design and deliver drug candidates for an undisclosed target...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details